Compare FMC Corp (FMC) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Johnson & Johnson — how do they compare? FMC Corp trades at $8.95 (market cap $1.39B), while Johnson & Johnson trades at $256.11 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 444.7× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.59%). Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Johnson & Johnson for 129 Days on average.
| FMC | JNJ | |
|---|---|---|
Market Cap | $1.39B | $618.09B |
Volume | 4,145,979 | 6,050,983 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $278.43 |
52-Week Low | $8.44 | $186.00 |
Typical Hold Time | 68 Days | 129 Days |
Enterprise Value | $5.19B | $646.37B |
Dividend Yield | 3.59% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $9.09, up 0.66% with bearish technical signals despite recent earnings beats. The agricultural sciences company faces severe profitability challenges with a -84.83% net margin and negative ROE, though valuation ratios appear attractive with P/S of 0.35 and P/B of 0.86. Recent developments include regulatory filings for new herbicides in Brazil and a minority equity investment from Tessenderlo Group.
While analyst consensus suggests moderate upside to the $14.60 price target, significant operational challenges and negative cash flow from operations in 2025 present substantial risks. The company's aggressive deleveraging efforts and new product pipeline offer potential catalysts, but investors face headwinds from cyclical industry pressures and persistent profitability issues.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
